Company news

Alvotech news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Alvotech Hosts Audio Call for Investors at 8: 15 am EDT on April 3, 2024

April 2, 2024

Alvotech Announces Increase in Number of Own Shares

March 21, 2024

Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update

March 19, 2024

Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8: 00 am ET

March 4, 2024

Alvotech Appoints Interim Chief Quality Officer

February 28, 2024

Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share

February 25, 2024

Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®

February 22, 2024

Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab)

February 14, 2024

Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®

January 28, 2024

Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04

January 18, 2024

Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea® (aflibercept)

January 2, 2024

Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®

November 28, 2023

Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update

November 27, 2023

Alvotech to Report Financial Results for the First Nine Months of 2023 on November 28, 2023, and Host Business Update Conference Call on November 29, 2023, at 8: 00 am ET

November 20, 2023

Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki™ (AVT04), the First Biosimilar of Stelara® (ustekinumab)

November 13, 2023

Alvotech Provides Update on Status of U.S. Biologics License Application for AVT04

October 11, 2023

Alvotech and Islandsbanki enter into Market Making Agreement for Shares Trading on Nasdaq Iceland

October 4, 2023

Alvotech Enters into Exclusive Licensing Agreement with Kashiv BioSciences for Development and Commercialization of a Proposed Biosimilar to Xolair® (omalizumab)

October 2, 2023

Alvotech Announces Approval in Japan of AVT04 (ustekinumab), a Biosimilar to Stelara®

September 24, 2023

Alvotech Provides U.S. Regulatory Update on AVT02, a High-Concentration Interchangeable Biosimilar Candidate to Humira® (adalimumab)

September 19, 2023

Alvotech Announces Changes to the Leadership Team

September 4, 2023

Alvotech Reports Financial Results for First Six Months of 2023 and Provides Business Update

August 29, 2023

Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) in Egypt

August 28, 2023

Alvotech to Report Financial Results for the First Half of 2023 on August 30, 2023, and Host Business Update Conference Call on August 31, 2023, at 8: 00 am ET

August 21, 2023

Alvotech Completes $100 Million Convertible Bond Private Placement

July 30, 2023

Alvotech Provides Regulatory Update on Second Biologics License Application for AVT02

June 27, 2023

Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®

June 11, 2023

Alvotech and Advanz Pharma extend strategic partnership to commercialize five proposed biosimilars in Europe

May 23, 2023

Alvotech Reports Financial Results for First three Months of 2023 and Provides Business Update

May 18, 2023

Alvotech Issues Annual Equality Report Covering 2022

May 14, 2023

Alvotech enters into commercialization agreement with Polifarma for proposed biosimilar to Eylea® (aflibercept)

May 9, 2023

Alvotech S.A. Annual General Meeting to be held June 6, 2023

May 4, 2023

Alvotech Initiates Confirmatory Patient Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®

May 3, 2023

Alvotech to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 18, 2023 and Host Conference Call on May 19, 2023 at 8: 00 am ET

May 2, 2023

Sarah Tanksley Joins Board of Directors for Alvotech hf. and Sandra Casaca Appointed Chief Quality Officer

April 18, 2023

Alvotech Provides Regulatory Update on AVT02 Biologics License Application

April 12, 2023

Alvotech Provides Update on Corporate Sustainability Framework

March 27, 2023

Alvotech to Present Clinical Study Data for AVT04, a Proposed Biosimilar to Stelara®, at 2023 American Academy of Dermatology (AAD) Annual Meeting

March 16, 2023

Alvotech Reports Financial Results for Full Year 2022 and Provides Business Update

February 28, 2023

Alvotech Announces Webcast of 2022 Full Year Financial Results at 8: 00 am ET on March 2, 2023

February 26, 2023

Settlement of Alvotech Private Share Placement Completed

February 9, 2023

Alvotech Enters Into Commercialization Agreement With Advanz Pharma for Proposed Biosimilar to Xolair® (Omalizumab)

February 5, 2023

Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) as Simlandi in Saudi Arabia

January 23, 2023

Alvotech Completes $137 Million Private Share Placement

January 22, 2023

Alvotech and Fuji Pharma Expand Partnership Adding a New Biosimilar Candidate

January 12, 2023

Alvotech Initiates Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®

January 10, 2023

Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)

January 5, 2023

Alvotech Completes $59.7 Million Private Placement

December 15, 2022

Alvotech Shares Start Trading on Nasdaq Iceland Main Market

December 7, 2022

Alvotech and STADA Broaden Access to Hukyndra® adalimumab biosimilar in Europe

December 6, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 17 calls. Every call is listed under its year.

Decks

The 5 newest of 11 decks. Every deck is listed under its year.